MAPK Cascade: The Three-Kinase Relay (Raf–MEK–ERK)

What the MAPK Cascade Is and Where It Runs

The MAPK cascade is a conserved three-kinase relay found in essentially all eukaryotes, from budding yeast to humans. Each of the three tiers is a protein kinase that activates the next by phosphorylation, so the module is often written MAP3K → MAP2K → MAPK. In the canonical growth-factor pathway the members are Raf → MEK → ERK.

• Where it happens: signaling begins at the plasma membrane, where a receptor tyrosine kinase (RTK) such as the EGF receptor recruits the adaptor Grb2 and the exchange factor SOS to load the small GTPase Ras with GTP.
• The relay: Ras-GTP recruits Raf to the membrane; activated Raf phosphorylates cytoplasmic MEK; MEK phosphorylates ERK; phospho-ERK dimerizes and translocates into the nucleus.

Humans run at least four parallel MAPK modules — the classical ERK1/2, plus JNK, p38, and ERK5 — each with its own MAP3K/MAP2K/MAPK trio wired to different inputs (mitogens vs. stress). This article focuses on the mitogen-driven ERK arm, the prototype for all of them.

The Mechanism, Step by Step

The cascade is a directed chain of covalent modifications:

• 1. Ras activation. Ligand binding dimerizes an RTK; autophosphorylated tyrosines dock Grb2–SOS, which catalyzes GDP→GTP exchange on Ras. Ras-GTP is the switch-on state.
• 2. Raf recruitment & activation. Ras-GTP binds Raf's RBD, pulls it to the membrane, relieves its autoinhibited conformation, and promotes side-to-side Raf dimerization — the true catalytic unit.
• 3. MEK activation. Active Raf phosphorylates MEK1/2 on two serines (S218 and S222) in the activation loop.
• 4. ERK activation. MEK is a rare dual-specificity kinase: it phosphorylates ERK on both a threonine and a tyrosine (Thr183 and Tyr185 in the T-E-Y motif). Both marks are required for full activity.
• 5. Output. Doubly-phosphorylated ERK phosphorylates cytoplasmic and nuclear substrates on Ser/Thr-Pro sites, then enters the nucleus.

Because ERK's dual phosphorylation is distributive (the kinase releases ERK between the two additions), the step behaves like a molecular AND-gate, sharpening the response.

Key Molecules, Amplification, and Characteristic Numbers

The named players and their quantitative behavior:

• Ras (~21 kDa; HRAS/KRAS/NRAS) — the membrane-anchored GTPase switch.
• Raf — three isoforms: ARAF, BRAF, CRAF/Raf-1; BRAF has the highest basal kinase activity.
• MEK1/2 (~45 kDa) — narrow-specificity dual kinases whose only physiological substrate is ERK.
• ERK1 (p44) / ERK2 (p42) — the terminal effectors, targeting 200+ substrates including the transcription factors Elk-1, c-Fos, and c-Myc, and the kinase RSK.

Amplification and ultrasensitivity: because each kinase turns over many downstream molecules, the multi-tier design multiplies signal and sharpens it. Huang and Ferrell (1996) showed the ERK output behaves ultrasensitively, with an effective Hill coefficient near nH ≈ 4–5 — a nearly switch-like response to graded input. Peak ERK phosphorylation typically appears ~5–10 minutes after growth-factor stimulation and, with negative feedback, can resolve within 30–60 minutes or oscillate.

How the Cascade Is Studied and Regulated

Regulation: the pathway is not one-way. Active ERK feeds back to phosphorylate and inhibit upstream SOS and Raf, and it induces dual-specificity phosphatases (DUSPs/MKPs) that dephosphorylate the T-E-Y motif to reset ERK. Scaffold proteins such as KSR and MP1 assemble Raf, MEK, and ERK into a complex, boosting fidelity and tuning whether the output is transient or sustained — a difference that in PC12 cells switches the cell between proliferation (transient ERK) and differentiation (sustained ERK), Marshall's classic 1995 finding.

• Phospho-antibodies & Western blot: anti-phospho-ERK (pT183/pY185) is the standard readout of pathway activity.
• Pharmacology: MEK inhibitors U0126 and PD98059 are canonical experimental blockers; trametinib and vemurafenib are clinical inhibitors.
• Live-cell reporters: FRET biosensors (EKAR) and ERK-KTR translocation reporters reveal single-cell pulsing dynamics invisible in bulk assays.

How It Compares to Related Signaling Processes

It helps to place the ERK cascade against its cousins and against other signaling logics:

• vs. JNK and p38 MAPKs: these are the stress-activated MAPKs (SAPKs), triggered by UV, osmotic shock, and cytokines rather than mitogens; they use different MAP3Ks (e.g., ASK1, MEKK) and MAP2Ks (MKK4/7, MKK3/6) but share the identical three-tier architecture.
• vs. the yeast pheromone pathway: the Ste11→Ste7→Fus3 mating cascade is the evolutionary blueprint — the same MAP3K/MAP2K/MAPK logic that inspired the mammalian model.
• vs. second-messenger cascades (cAMP–PKA): those amplify through diffusible small molecules; the MAPK relay instead amplifies through sequential covalent phosphorylation, giving spatial control and ultrasensitivity.
• vs. a single kinase: one enzyme gives a graded, Michaelian response; the three-tier design converts that into a sharp, switch-like decision.

Significance, Disease, and Open Questions

The Ras–Raf–MEK–ERK axis is arguably the most important oncogenic pathway in medicine. Activating mutations somewhere along it appear in roughly 30% of all human cancers. KRAS is the most frequently mutated oncogene (common in pancreatic, colorectal, and lung tumors), and the single substitution BRAF V600E — valine to glutamate at codon 600, which makes Raf constitutively active as a monomer — is found in about 50% of melanomas and in most hairy-cell leukemias and papillary thyroid cancers.

• Targeted therapy: the BRAF-V600E inhibitor vemurafenib (PLX4032) and MEK inhibitor trametinib produce dramatic melanoma responses; combining them delays resistance.
• Developmental disease: germline mutations in the pathway cause the "RASopathies" — Noonan, cardiofaciocutaneous, and Costello syndromes.

Open questions: Why does the same ERK signal specify proliferation in one context and differentiation in another? How do single-cell ERK pulses encode information? And how do tumors so reliably reactivate ERK after inhibition — a puzzle driving next-generation ERK and pan-Raf drugs.

The three tiers of the canonical Raf–MEK–ERK cascade and their properties

Tier	Enzyme (human)	Family / role	Activated by	Key phosphorylation
MAP3K	Raf-1 / BRAF / ARAF	MAPKKK — activated by Ras-GTP	Ras-GTP + membrane recruitment	Phosphorylates MEK on two Ser (S218/S222)
MAP2K	MEK1 / MEK2	MAPKK — dual-specificity kinase	Raf	Phosphorylates ERK on Thr183 and Tyr185 (TEY motif)
MAPK	ERK1 (p44) / ERK2 (p42)	Terminal effector kinase	MEK	Phosphorylates ~200+ substrates (S/T-P sites)
Off-switch	MKPs / DUSPs, PP2A	Phosphatases	Induced by ERK (feedback)	Removes phosphates from TEY, resets ERK